Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
A recurrence risk of less than 0.5% at 6 years after surgery may provide a practical definition of “cure” in the setting of colon cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback